Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 152 No. 1314 (2022)

Long-term follow-up for childhood cancer survivors: the Geneva experience

  • Shai Babecoff
  • Florence Mermillod
  • Denis Marino
  • Angèle Gayet-Ageron
  • Marc Ansari
  • Eugenio Fernandez
  • Fabienne Gumy-Pause
DOI
https://doi.org/10.4414/SMW.2022.w30153
Cite this as:
Swiss Med Wkly. 2022;152:w30153
Published
07.04.2022

Summary

AIMS OF THE STUDY: Although the 5-year survival for pediatric cancer in Switzerland today is over 85%, two thirds of the survivors will develop chronic health conditions due to the disease or to the toxicity of treatments. In this context, a long-term personalized follow-up program (LTFU program), was set up at the University Hospitals of Geneva (HUG) since 2015. We aimed to describe this program, more particularly the specialized follow-ups set up, the cumulative burden of the chronic health conditions, and finally assess the satisfaction of patients and/or their parents with it.

METHODS: A monocentric retrospective study was performed where data on follow-ups and chronic health conditions were collected from medical charts of people who had childhood cancer and who participated in the LTFU program. Chronic health conditions were classified and graded in severity with the Common Terminology Criteria of Adverse Events (CTCAE) classification, version 5.0. This study was completed by a satisfaction survey among patients and/or their parents.

RESULTS: Out of 83 eligible patients, 51 (61.4%) accepted to participate, with an average age of 17.4 years (range, 10 to 35) at the time of study. Mean delay since end of treatment was 9.8 years (range: 4.5–31). The prevalence of any chronic health condition is 82.3%, 43.1% for having 1 or 2 chronic health conditions and 39.2% for having more than 3 chronic health conditions. The total number of Grade CTCAE 1–4 chronic health conditions was 118 for the 51 participants, with a mean of 2.3 (range, 0 to 7) disorders per patient. The most frequently affected systems were neurological (14.4%), musculoskeletal (13.6%), endocrine (9.3%) and renal (9.3%) systems. Sarcoma, central nervous system tumors and neuroblastoma were the diagnoses associated with the highest average number of chronic health conditions. Among the 118 questionnaires sent to patients and/or parents, we received 82 (69.5%) responses. The level of satisfaction was good to excellent for more than 90% of the participants, for all the items evaluated.

CONCLUSIONS: Childhood cancer survivors present a significant number of chronic health conditions, confirming the need for appropriate long-term, multidisciplinary and patient-specific medical follow-up based on the primary diagnosis and therapies received. Moreover, the LTFU program at the HUG was highly appreciated by patients and/or their parents and this motivates its permanent conduct.

References

  1. Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, et al.; EUROCARE Working Group. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer. 2009 Apr;45(6):992–1005. https://doi.org/10.1016/j.ejca.2008.11.042
  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013 Jan;63(1):11–30. https://doi.org/10.3322/caac.21166
  3. Swiss Childhood Cancer Registry [Internet]. Bern: Swiss Childhood Cancer Registry; 2019 [cited 2020 July 13]. Availbale from https://www.kinderkrebsregister.ch/wp-content/uploads/sites/2/2019/09/FINAL-Annual-Report_2017_2018_with-CC-license.pdf
  4. Bleyer A, O’Leary M, Barr R, et al. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. Bethesda, MD: National Cancer Institute, 2006.
  5. Ries LG, Pollack ES, Young JL Jr. Cancer patient survival: Surveillance, Epidemiology, and End Results Program, 1973-79. J Natl Cancer Inst. 1983 Apr;70(4):693–707.
  6. Oeffinger KC, Robison LL. Childhood cancer survivors, late effects, and a new model for understanding survivorship. JAMA. 2007 Jun;297(24):2762–4. https://doi.org/10.1001/jama.297.24.2762
  7. Diller L, Chow EJ, Gurney JG, Hudson MM, Kadin-Lottick NS, Kawashima TI, et al. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol. 2009 May;27(14):2339–55. https://doi.org/10.1200/JCO.2008.21.1953
  8. Mertens AC, Liu Q, Neglia JP, Wasilewski K, Leisenring W, Armstrong GT, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2008 Oct;100(19):1368–79. https://doi.org/10.1093/jnci/djn310
  9. Schindler M, Spycher BD, Ammann RA, Ansari M, Michel G, Kuehni CE ; Swiss Paediatric Oncology Group (SPOG). Cause-specific long-term mortality in survivors of childhood cancer in Switzerland: A population-based study. Int J Cancer. 2016 Jul;139(2):322–33. https://doi.org/10.1002/ijc.30080
  10. Bhakta N, Liu Q, Ness KK, Baassiri M, Eissa H, Yeo F, et al. The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet. 2017 Dec;390(10112):2569–82. https://doi.org/10.1016/S0140-6736(17)31610-0
  11. Erdmann F, Frederiksen LE, Bonaventure A, Mader L, Hasle H, Robison LL, et al. Childhood cancer: Survival, treatment modalities, late effects and improvements over time. Cancer Epidemiol. 2021 Apr;71 Pt B:101733. https://doi.org/10.1016/j.canep.2020.101733
  12. F. Gumy-Pause*, E.M. Tinner*, M. Diezi, E. Bergsträsser, H. Hengartner, B. Eisenreich, P. Brazzola, N. von der Weid, Z. Tomášiková, K. Scheinemann, Long-term follow-up after childhood cancer in Switzerland: a position statement from the pediatric Swiss LTFU working group. Bulletin suisse du cancer (2019) 39 : 212-215.
  13. Children’s Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancer Version 4.0 [Internet]. Seattle: Children’s Oncology Group; 2013 [updated 2013 October; cited 2020 July 18]. Available from: http://www.survivorshipguidelines.org/pdf/COG%20LTFU%20Guidelines%20Archive/Version%204.0/COG_LTFU_Guidelines_v4%20(secured).pdf
  14. Kazak AE, Hocking MC, Ittenbach RF, Meadows AT, Hobbie W, DeRosa BW, et al. A revision of the intensity of treatment rating scale: classifying the intensity of pediatric cancer treatment. Pediatr Blood Cancer. 2012 Jul;59(1):96–9. https://doi.org/10.1002/pbc.23320
  15. Lansky SB, List MA, Lansky LL, Ritter-Sterr C, Miller DR. The measurement of performance in childhood cancer patients. Cancer. 1987 Oct;60(7):1651–6. https://doi.org/10.1002/1097-0142(19871001)60:7<1651::AID-CNCR2820600738>3.0.CO;2-J
  16. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutics in cancer. In: MacLoed CM, ed. Evaluation of Chemotherapeutic Agents. New York: Columbia University Press; 1949: p. 191-205.
  17. National Cancer Institute. Division of Cancer Treatment & Diagnosis. Cancer Therapy Evaluation Program [Internet]. Bethesda: National Cancer Institute; 2020 [updated 2020 March 27; cited 2020 July 17]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
  18. Oeffinger KC, Hudson MM, Landier W. Survivorship: childhood cancer survivors. Prim Care. 2009 Dec;36(4):743–80. https://doi.org/10.1016/j.pop.2009.07.007
  19. Suh E, Stratton KL, Leisenring WM, Nathan PC, Ford JS, Freyer DR, et al. Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study. Lancet Oncol. 2020 Mar;21(3):421–35. https://doi.org/10.1016/S1470-2045(19)30800-9
  20. Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013 Jun;309(22):2371–81. https://doi.org/10.1001/jama.2013.6296
  21. Phillips SM, Padgett LS, Leisenring WM, Stratton KK, Bishop K, Krull KR, et al. Survivors of childhood cancer in the United States: prevalence and burden of morbidity. Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):653–63. https://doi.org/10.1158/1055-9965.EPI-14-1418
  22. Gibson TM, Mostoufi-Moab S, Stratton KL, Leisenring WM, Barnea D, Chow EJ, et al. Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2018 Dec;19(12):1590–601. https://doi.org/10.1016/S1470-2045(18)30537-0
  23. Ussher JM, Perz J. Infertility-related distress following cancer for women and men: A mixed method study. Psychooncology. 2019 Mar;28(3):607–14. https://doi.org/10.1002/pon.4990
  24. Michel G, Rebholz CE, von der Weid NX, Bergstraesser E, Kuehni CE. Psychological distress in adult survivors of childhood cancer: the Swiss Childhood Cancer Survivor study. J Clin Oncol. 2010 Apr;28(10):1740–8. https://doi.org/10.1200/JCO.2009.23.4534
  25. Berger C, Casagranda L, Faure-Conter C, Freycon C, Isfan F, Robles A, et al. Long-Term Follow-up Consultation After Childhood Cancer in the Rhône-Alpes Region of France: Feedback From Adult Survivors and Their General Practitioners. J Adolesc Young Adult Oncol. 2017 Dec;6(4):524–34. https://doi.org/10.1089/jayao.2017.0019
  26. Christen S, Vetsch J, Mader L, Dehler S, Korol D, Kuehni C, et al. Preferences for the organization of long-term follow-up in adolescent and young adult cancer survivors. Support Care Cancer. 2016 Aug;24(8):3425–36. https://doi.org/10.1007/s00520-016-3157-7

Most read articles by the same author(s)